Cara Therapeutics (CARA) Presents At 41st Annual Healthcare Conference - Slideshow

RUN-IN Double Blind Treatment Period Long-term Safety Extension Treatment Period (Open Label) 7 Days 8 Weeks Up to 52 Weeks Part B and Second Study Oral DFK XX mg BID Oral PBO BID Initiation Part A NP Phase 2/3 (1Q 2023) | --- | |-------------| | | | | | KIND 1b & 2 | | AD Phase 3 | 15 $180M cash position September 30, 2022 • Sufficient resources to continue development of the oral difelikefalin platforms CCARA THERAPEUTICS Prim ary Endpoint KARE STUDY: Phase 2 Data in Atopic Dermatitis (AD) Popula t ion: M ...